These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5875 related articles for article (PubMed ID: 3457206)

  • 21. Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis.
    Ambrus JL; Ambrus CM; Gastpar H; Williams P
    J Med; 1982; 13(1-2):35-47. PubMed ID: 6288824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clinical study of nafazatrom in advanced human breast cancer.
    Jones AL; Powles TJ; Forgeson GV; Coombes RC
    Cancer Chemother Pharmacol; 1991; 27(4):326-8. PubMed ID: 1998990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between dose, pharmacokinetics, plasma-concentrations and antithrombotic effects of nafazatrom.
    Philipp E; Ritter W; Patzschke K
    Thromb Res Suppl; 1983; 4():129-33. PubMed ID: 6579706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I clinical study of nafazatrom.
    Hortobagyi GN; Papadoupoulos NE; Frye D; Ajani J; Reuben JM
    Invest New Drugs; 1986; 4(3):251-5. PubMed ID: 3818230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Modification of metastasis formation by inhibition of platelet aggregation. Experimental and clinical results].
    Gastpar H
    Laryngol Rhinol Otol (Stuttg); 1983 Dec; 62(12):578-85. PubMed ID: 6369051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultrastructural observations of an electron dense amorphous layer on selectively damaged endothelial cells, a possible trigger of thrombogenesis in vivo, and its inhibition by nafazatrom.
    Herrmann KS; Voigt WH
    Thromb Res; 1984 Nov; 36(3):205-15. PubMed ID: 6083613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
    Savion N; Disatnik MH; Nevo Z
    J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet aggregation in arterioles of the hamster cheek pouch and in heart transplants: its tissue-dependent influencibility by acetylsalicylic acid and nafazatrom.
    Herrmann KS; Seuter F
    Haemostasis; 1984; 14(3):281-7. PubMed ID: 6381254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells.
    Humphries MJ; Yamada KM; Olden K
    J Clin Invest; 1988 Mar; 81(3):782-90. PubMed ID: 3343338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective degradation of basement membrane macromolecules by metastatic melanoma cells.
    Kramer RH; Vogel KG
    J Natl Cancer Inst; 1984 Apr; 72(4):889-99. PubMed ID: 6584663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
    Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
    Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic tumor cells adhere preferentially to the extracellular matrix underlying vascular endothelial cells.
    Kramer RH; Gonzalez R; Nicolson GL
    Int J Cancer; 1980 Nov; 26(5):639-45. PubMed ID: 7239720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tunicamycin on B16 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties.
    Irimura T; Gonzalez R; Nicolson GL
    Cancer Res; 1981 Sep; 41(9 Pt 1):3411-8. PubMed ID: 7260906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of nafazatrom.
    Seuter F; Busse WD
    Thromb Res Suppl; 1983; 4():75-80. PubMed ID: 6415860
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of basement membrane matrix degradation by purified proteases and by metastatic tumor cells.
    Starkey JR; Stanford DR; Magnuson JA; Hamner S; Robertson NP; Gasic GJ
    J Cell Biochem; 1987 Sep; 35(1):31-49. PubMed ID: 3312246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrosphelide B suppressed metastasis through inhibition of adhesion of sLe(x)/E-selectin molecules.
    Fukami A; Iijima K; Hayashi M; Komiyama K; Omura S
    Biochem Biophys Res Commun; 2002 Mar; 291(4):1065-70. PubMed ID: 11866473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical trial of nafazatrom (Bay g 6575) in advanced cancer.
    O'Donnell JF; Blakowski SA; Zacharski LR; Nierenberg DW; Coughlin CT; Fein S; Philipp E; Cornwell GG
    Am J Clin Oncol; 1986 Apr; 9(2):152-5. PubMed ID: 3717082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats.
    Feuerstein G; Bayorh MA; Stull R; Goldstein DS; Zerbe RL; Ramwell PW; Faden AI
    Circ Shock; 1985; 17(3):223-32. PubMed ID: 3841032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells.
    Schultz RM; Silberman S; Persky B; Bajkowski AS; Carmichael DF
    Cancer Res; 1988 Oct; 48(19):5539-45. PubMed ID: 3416307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis.
    Tang YM; Cao QY; Guo XY; Dong SH; Duan JA; Wu QN; Liang QL
    Biomed Pharmacother; 2018 Feb; 98():382-389. PubMed ID: 29276966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 294.